During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

Vallina, from the CRIS Immuno-Oncology Unit, in Madrid (Spain), explains that a new approach provides 'trained troops' of ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...

“I am honored to have been named a K12 scholar,” says McNerney. “To me, this represents Northwestern’s commitment to my ...

Adicet Bio (ACET) reported ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ...

immune system T-cells "are taken from the patient's blood and are changed in the lab by adding a gene for a receptor (called ...

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...

Rundell found some of the imaginary animals that populate “Impossible Creatures” in old manuscripts, while researching for ...